| An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model. | |
| | |
MedLine Citation:
|
PMID: 21053746 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND AIM OF THE STUDY: Cholesterol is a known risk factor in aortic stenosis and valve degeneration, and the liver X receptor (LXR) is a regulator of cholesterol and phospholipid metabolism. It was hypothesized that an LXR agonist would reduce calcium and lipid deposition in aortic valves. METHODS: Apolipoprotein E-/- (ApoE-/-) mice fed a high-fat diet were implanted with glutaraldehyde-fixed porcine valve fragments. The animals were treated with either the LXR agonist T1317 or vehicle for eight weeks. RESULTS: The LXR agonist reduced lipid deposition in native aortic roots and sinuses about two-fold (p < 0.05), and echocardiography revealed lower transvalvular velocities in vivo (p < 0.05). Similarly, treatment with the LXR agonist significantly reduced the calcium content (by ca. 50%, p < 0.05) and lipid content (by ca. 20%, p < 0.01) of explanted porcine valve tissue. Serum low-density lipoprotein (LDL) and total cholesterol levels were also lower in treated mice (p < 0.01). Serum levels of the inflammatory chemokine platelet factor 4 were reduced by 30% compared to controls. Cultured valvular cells treated with oxidized LDL (ox-LDL) developed greater numbers of calcific nodules. The ox-LDL treatment of valvular endothelial cells increased adhesion to mononuclear cells, while the LXR agonist reversed both the increase in adhesion and vascular cell adhesion protein-1 expression mediated by ox-LDL. CONCLUSION: The data acquired suggested that calcium and lipid deposition in heart valves can be altered by inhibiting lipid metabolism via LXR, and that the mechanism may involve inflammatory cell signaling. These results indicate that enhancement of cholesterol efflux activity may have the potential to reduce bioprosthetic and native valve degeneration. |
| | |
Authors:
|
Haimei Wang; Sorel Goland; Kevin Burton; Lawrence S C Czer; Ernst R Schwarz; Alfredo Trento |
Related Documents
:
|
2804066 - Cholesterol removal by peritoneal lavage with phospholipid-hdl apoprotein mixtures in h... 7929116 - Production of cholesterol-enriched nascent high density lipoproteins by human monocyte-... 19661486 - Macrophage reverse cholesterol transport in mice expressing apoa-i milano. 16258026 - Reverse cholesterol transport and cholesterol efflux in atherosclerosis. 16641546 - A two-generation reproductive toxicity study of diethyl phthalate (dep) in rats. 3470306 - Different patterns of postprandial lipoprotein metabolism in normal, type iia, type iii... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of heart valve disease Volume: 19 ISSN: 0966-8519 ISO Abbreviation: J. Heart Valve Dis. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: 2010-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9312096 Medline TA: J Heart Valve Dis Country: England |
Other Details:
|
Languages: eng Pagination: 653-64 Citation Subset: IM |
Affiliation:
|
Division of Cardiothoracic Surgery, Department of Surgery, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Davis Building Room 6014, Los Angeles, California 90048, USA. Haimei.Wang@hsc.utah.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Aortic Valve / cytology, drug effects, metabolism Apolipoproteins E / genetics, metabolism Calcium / metabolism Cell Adhesion / drug effects Cells, Cultured Disease Models, Animal Female Heart Valve Diseases / etiology*, metabolism, prevention & control* Heart Valve Prosthesis Hydrocarbons, Fluorinated / pharmacology, therapeutic use* Hypercholesterolemia / complications* Lipid Metabolism / drug effects Lipoproteins, LDL / pharmacology Mice Mice, Inbred C57BL Mice, Knockout Orphan Nuclear Receptors / agonists* Sulfonamides / pharmacology, therapeutic use* Swine |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoproteins E; 0/Hydrocarbons, Fluorinated; 0/Lipoproteins, LDL; 0/Orphan Nuclear Receptors; 0/Sulfonamides; 0/TO-901317; 0/liver X receptor; 0/oxidized low density lipoprotein; 7440-70-2/Calcium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mid-term follow up of triple valve surgery in a western community: predictors of survival.
Next Document: Usefulness of computed tomography scanning in the diagnosis of aortic prosthetic valve pannus.